Company Emyria Limited

Equities

EMD

AU0000073645

Healthcare Facilities & Services

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Sector Hospitals, Clinics & Primary Care Services

Market Closed - Australian S.E. Other stock markets 01:55:19 2024-04-26 am EDT			5-day change	1st Jan Change
0.049 ^AUD	-3.92%		-12.50%	-5.77%

Apr. 23	Emyria to Raise AU$2.3 Million via Placement	MT
Apr. 10	Emyria Launches Empax Center	MT

Emyria Limited is an Australia-based clinical services and drug development company. The Company is focused on developing patient outcomes in neuroscience and mental health through its clinical service delivery, proprietary real-world data (RWD), and drug discovery & development. It delivers evidence-based and emerging therapies for mental health and other unmet needs through its Emerald Clinics and the Pax Centre. Emerald Clinics specializes in providing treatments for patients with complex and chronic conditions. The Pax Centre specializes in treating individuals grappling with the psychological impacts of traumatic experiences. Through its advanced data platform operated by Palantir, the Company collects robust and ethically sourced real-world data to improve its care models and support its distinct therapy and drug development initiatives. The Company is also developing several proprietary ultra-pure cannabinoid dose forms and advancing them towards registration, such as EMD-RX5.

AUD in Million	2022	Weight	2023	Weight	Delta
Patients 93.4 %	1	74.2 %	1	93.4 %	+9.94%
Research Projects and Data Deals 6.6 %	0	25.8 %	0	6.6 %	-77.57%

AUD in Million	2022	Weight	2023	Weight	Delta
Australia 100.0 %	2	100.0 %	2	100.0 %	-12.62%

Managers	Title	Age	Since
Michael Winlo CEO	Chief Executive Officer	-	19-10-02
Joseph Ohayon DFI	Director of Finance/CFO	-	-
Mary Ann Rennie COO	Chief Operating Officer	-	-
Tracie Ernenwein CTO	Chief Tech/Sci/R&D Officer	-	-
Lexi O’Halloran IRC	Investor Relations Contact	-	-
Margaret Somerville PRN	Corporate Officer/Principal	-	-
Susan Park SEC	Corporate Secretary	49	23-02-28

Members of the board	Title	Age	Since
Mohit Kaushal BRD	Director/Board Member	45	23-08-20
John Tooke BRD	Director/Board Member	75	18-03-22
Karen Smith BRD	Director/Board Member	56	21-11-28
Greg Hutchinson CHM	Chairman	-	Nov. 20
Michael Winlo CEO	Chief Executive Officer	-	19-10-02

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	366,629,396	203,457,666 ( 55.49 %)	0	55.49 %

Name	Equities	%	Valuation
Matthew Callahan 5.361 %	19,655,556	5.361 %	756 542 $
Greg Hutchinson 0.1364 %	500,000	0.1364 %	19 245 $
Michael Winlo 0.1325 %	485,794	0.1325 %	18 698 $

Emyria Ltd.

D2 661 Newcastle Street

6007, Leederville

http://emyria.com

Healthcare

Healthcare Services

Healthcare Providers & Services

Healthcare Facilities & Services

Hospitals, Clinics & Primary Care Services

	1st Jan change	Capi.
EMYRIA LIMITED	-5.77%	12.16M
AIER EYE HOSPITAL GROUP CO., LTD.	-20.16%	15.76B
BANGKOK DUSIT MEDICAL SERVICES	+4.50%	12.34B
IHH HEALTHCARE	+3.98%	11.52B
APOLLO HOSPITALS ENTERPRISE LIMITED	+9.72%	11.02B
ENCOMPASS HEALTH CORPORATION	+23.61%	8.28B
RAMSAY HEALTH CARE LIMITED	-2.19%	7.8B
MOUWASAT MEDICAL SERVICES COMPANY	+20.75%	7.2B
THE ENSIGN GROUP, INC.	+4.49%	6.67B
GLOBAL HEALTH LIMITED	+50.89%	4.64B

Hospitals, Clinics & Primary Care Services